pegfilgrastim

FDA Drug Profile — Neulasta, FYLNETRA

pegfilgrastim is listed in the FDA National Drug Code directory with 11 NDC codes, marketed under brand names including Neulasta, FYLNETRA. Available dosage forms: solution, kit, injection, liquid.

Drug details

Generic Name
pegfilgrastim
Brand Names
Neulasta, FYLNETRA
Application Number
BLA125031
Sponsor
Amgen, Inc
NDC Codes
11
Dosage Forms
SOLUTION, KIT, INJECTION, LIQUID
Routes
SUBCUTANEOUS
Active Ingredients
PEGFILGRASTIM

Indications and Usage

1 INDICATIONS AND USAGE FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (1.1) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). (1.2) Limitations of Use FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy FYLNETRA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14.1) ] . Limitations of Use FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome FYLNETRA is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration (2.2) and Clinical Studies (14.2) ] .

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.